Literature DB >> 10606368

A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease.

T V Vu1, A Escalante.   

Abstract

OBJECTIVE: To compare health related quality of life between patients with lupus nephritis who progressed to endstage renal disease (ESRD) and patients with systemic lupus erythematosus (SLE) with preserved renal function.
METHODS: Patients with SLE undergoing maintenance renal dialysis and SLE patients with preserved renal function completed the Medical Outcomes Study Short Form-36 and social support questionnaires and the Center for Epidemiologic Studies Depression Scale. SLE disease activity and organ damage were measured by the SLE Disease Activity Index and Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index.
RESULTS: We studied 104 patients with SLE: 22 undergoing maintenance renal dialysis and 82 with preserved renal function. Their scores in all 8 of the SF-36 scales were reduced compared to national norms. Patients with ESRD had significantly higher mental health scores (mean +/- standard error 71.3 +/-4.8 vs. 60.7+/-2.5; p = 0.05), but there were no significant differences between the 2 groups in the remaining SF-36 scales. Multivariate models adjusting for demographic, socioeconomic, and clinical characteristics and for symptoms of depression revealed that being on dialysis was associated with higher mental health scores (regression coefficient = 12.97, 95% confidence interval 2.72 to 23.22), but lower physical function [-11.28 (-22.43 to -0.12)] and general health [-10.94 (-21.31 to -0.57)].
CONCLUSION: Patients with lupus nephritis who progress to endstage renal disease have improved mental well being but reduced physical function and general health. Strategies to improve the quality of life of patients with SLE are needed.

Entities:  

Mesh:

Year:  1999        PMID: 10606368

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.

Authors:  Rina Mina; Emily von Scheven; Stacy P Ardoin; B Anne Eberhard; Marilynn Punaro; Norman Ilowite; Joyce Hsu; Marisa Klein-Gitelman; L Nandini Moorthy; Eyal Muscal; Suhas M Radhakrishna; Linda Wagner-Weiner; Matthew Adams; Peter Blier; Lenore Buckley; Elizabeth Chalom; Gaëlle Chédeville; Andrew Eichenfield; Natalya Fish; Michael Henrickson; Aimee O Hersh; Roger Hollister; Olcay Jones; Lawrence Jung; Deborah Levy; Jorge Lopez-Benitez; Deborah McCurdy; Paivi M Miettunen; Ana I Quintero-del Rio; Deborah Rothman; Ornella Rullo; Natasha Ruth; Laura E Schanberg; Earl Silverman; Nora G Singer; Jennifer Soep; Reema Syed; Larry B Vogler; Ali Yalcindag; Cagri Yildirim-Toruner; Carol A Wallace; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

2.  Long-term outcome of patients with lupus nephritis: a single center experience.

Authors:  Senija Rasić; Amira Srna; Snezana Uncanin; Jasminka Dzemidzić; Damir Rebić; Alma Muslimović; Maida Rakanović-Todić; Aida Hamzić-Mehmedbasić
Journal:  Bosn J Basic Med Sci       Date:  2010-04       Impact factor: 3.363

3.  Quality of life in patients with systemic lupus erythematosus (SLE) compared with related controls within a unique African American population.

Authors:  A Barnado; L Wheless; A K Meyer; G S Gilkeson; D L Kamen
Journal:  Lupus       Date:  2011-10-26       Impact factor: 2.911

4.  Health-related quality of life and employment among persons with systemic lupus erythematosus.

Authors:  Jinoos Yazdany; Edward Yelin
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

5.  Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.

Authors:  C Alejandro Arce-Salinas; Felipe Rodríguez-García; J Iván Gómez-Vargas
Journal:  Rheumatol Int       Date:  2011-01-22       Impact factor: 2.631

6.  Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome).

Authors:  Meral Calguneri; Zeynep Ozbalkan; M Akif Ozturk; Sule Apras; A Ihsan Ertenli; Sedat Kiraz
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 2.980

Review 7.  Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma.

Authors:  Chi Chiu Mok
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

Review 8.  The socioeconomic burden of SLE.

Authors:  Chak Sing Lau; Anselm Mak
Journal:  Nat Rev Rheumatol       Date:  2009-06-09       Impact factor: 20.543

9.  Efficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis.

Authors:  Jian Sun; Hao Zhang; Ying Ji; Ming Gui; Bin Yi; Jianwen Wang; Juan Jiang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 10.  Lupus nephritis.

Authors:  Hans-Joachim Anders; Ramesh Saxena; Ming-Hui Zhao; Ioannis Parodis; Jane E Salmon; Chandra Mohan
Journal:  Nat Rev Dis Primers       Date:  2020-01-23       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.